Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kendle International, a clinical research organization, has completed the acquisition of the phase II-IV clinical services business of Charles River Laboratories for $215 million.
Subscribe to our email newsletter
The move strengthens Kendle’s position in the clinical development industry, adding therapeutic expertise, diversifying its customer base and expanding its capacity to deliver large global trials.
With the completion of the acquisition, Kendle now has nearly 3,000 associates in operations throughout North America, Europe, Asia/Pacific, Latin America and Africa. The combined organization is the fourth largest provider of phase II-IV clinical development services worldwide.
“Our newly combined organization offers our customers an expanded global platform and broadened therapeutic base for their drug development efforts, and positions Kendle for continued strong growth as we accelerate toward our $500 million mid-term revenue goal,” commented Dr Candace Kendle, chairman and CEO.